<DOC>
	<DOCNO>NCT00475085</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug , granisetron , dexamethasone , prochlorperazine , aprepitant , palonosetron , may help lessen prevent nausea . It yet know combination antiemetic drug effective prevent nausea cause chemotherapy . PURPOSE : This randomized phase III trial compare different combination granisetron , dexamethasone , prochlorperazine , aprepitant , palonosetron see well work prevent nausea patient undergo chemotherapy breast cancer .</brief_summary>
	<brief_title>Prevention Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy palonosetron hydrochloride dexamethasone follow prochlorperazine v without dexamethasone prevent delay nausea woman chemotherapy-naive breast cancer . ( Arms I IV ) - Determine palonosetron hydrochloride effective granisetron hydrochloride control treatment-related delayed nausea patient . ( Arms I II ) - Determine currently recommend antiemetic guideline aprepitant combine palonosetron hydrochloride dexamethasone effective antiemetic regimen control treatment-related delayed nausea patient . ( Arms III IV ) Secondary - Determine addition dexamethasone prochlorperazine effective regimen without dexamethasone reduce interference functioning cause chemotherapy-induced nausea vomit patient . ( Arms I IV ) - Determine palonosetron hydrochloride effective granisetron hydrochloride reduce interference functioning cause chemotherapy-induced nausea vomit patient . ( Arms I II ) - Determine currently recommend antiemetic guideline aprepitant combine palonosetron hydrochloride dexamethasone effective antiemetic regimen reduce interference function due chemotherapy-induced nausea vomit patient . ( Arms III IV ) OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord CCOP center gender . Patients randomize 1 4 treatment arm . Patients receive study treatment approximately 30 minute schedule first chemotherapy treatment . - Arm I : Patients receive palonosetron hydrochloride IV , dexamethasone IV , oral placebo day 1 oral prochlorperazine 3 time daily another oral placebo daily day 2 3 . - Arm II : Patients receive granisetron hydrochloride IV , dexamethasone IV , oral placebo day 1 oral prochlorperazine 3 time daily another oral placebo daily day 2 3 . - Arm III : Patients receive palonosetron hydrochloride IV dexamethasone IV day 1 , oral aprepitant daily day 1-3 , oral dexamethasone daily oral placebo twice daily day 2 3 . - Arm IV : Patients receive palonosetron hydrochloride IV , dexamethasone IV , oral placebo day 1 oral prochlorperazine 3 time daily oral dexamethasone daily day 2 3 . Quality life assess baseline day 4 . Nausea vomiting , fatigue , sleep quality , exercise , need rescue medication ( metoclopramide ) assess day 1-4 . PROJECTED ACCRUAL : A total 890 patient accrue study .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Inclusion criterion : Have diagnosis cancer chemotherapy naive . Must schedule receive chemotherapy treatment contain doxorubicin hydrochloride , epirubicin hydrochloride , cisplatin , carboplatin , oxaliplatin ( dose schedule ) without concurrent radiotherapy interferon treatment Chemotherapy may adjuvant , neoadjuvant , curative palliative intent . Dosedense regimens ( e.g . chemotherapy doxorubicin epirubicin give every two week ) allow . For purpose study , Day 1 chemotherapy define day administration cisplatin , carboplatin , oxaliplatin , doxorubicin epirubicin . Regimens multipleday dos doxorubicin , epirubicin , cisplatin , carboplatin , oxaliplatin , dacarbazine , hexamethylmelamine , nitrosoureas , streptozocin allow . Chemotherapy agent , list , may give orally , intravenously , continuous infusion one multiple day . Able understand English Exclusion criterion : No symptomatic brain metastases No concurrent impend bowel obstruction Regimens contain liposomal doxorubicin cisplatin allow . No concurrent pimozide , terfenadine , astemizole , cisapride No concurrent doxorubicin hydrochloride liposome cisplatin No concurrent multipleday dose dacarbazine , altretamine , nitrosoureas , streptozocin , cisplatin , carboplatin , oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>